Pharmaceutical Products for CDER Research Studies - IDIQ
Closed Solicitation Posted
This opportunity was awarded. See the award notice from .
- Solicitation number
- 75F40126Q132721
- Agency
-
FDA Office of Acquisition and Grant Services
Food and Drug Administration, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The FDA Office of Acquisition and Grant Services seeks a reliable supplier of currently marketed pharmaceutical drug products for Center for Drug Evaluation and Research studies under an IDIQ contract, with quotations due May 15, 2026 at 1:00 P.M. Central Time. This is unrestricted full and open competition with no small business set-aside.
Place of performance is the United States, with deliveries to FDA offices, external research sites, and international locations. The incumbent contractor is WE Pharma, LLC, under previous contract 75F40120D00032 (September 30, 2020 through September 29, 2025) with a prior IDIQ ceiling of $9,500,000.
The contract covers brand name and generic pharmaceuticals spanning small molecule therapeutics, peptide therapeutics, drug-device combination products, and contrast agents. The comprehensive drug product list in Attachment 1 specifies 96 pharmaceutical products; contractors must submit firm fixed pricing for all listed items and indicate which products they can supply. Delivery requirements mandate seven business days for domestic FDA offices and research sites, and 14 business days for international locations. All shipping and handling costs must be included in quoted prices under FOB Destination terms.
Contract structure spans five one-year ordering periods from September 1, 2026 through August 31, 2031, with a guaranteed minimum of $25,000 and an estimated maximum not to exceed $4,000,000 across all periods, though this ceiling may increase by mutual agreement. NAICS code is 325412 with a small business size standard of 1,300 employees. Evaluation weighs technical capability and past performance more heavily than price unless deemed essentially equal among offerors. Quotations must include completed pricing attachment, technical specifications, past performance information within three years, a small business subcontracting plan (unless offeror is small business or has an approved commercial plan), and an Accessibility Conformance Report for Section 508 non-compliance items. Contracting officer is Nick Sartain at (301) 796-1988; payment is net 30 days after government acceptance through the Department of Treasury's Invoice Processing Platform.
Notice text
3 versions
Update #3 · Latest ·
5/11/2026:
Questions and answers:
- Current or most recent incumbent contractor/vendor name
Response: WE Pharma, LLC
- Previous contract number and/or SAM.gov solicitation number
Response: Previous contract number 75F40120D00032 and solicitation number FDASOL1222072.
- Contract award value or estimated annual spend
Response: The prior IDIQ Ceiling was $9,500,000.00.
- Historical pricing information or awarded pricing structure
Response: Historical pricing information and awarded pricing structure are not being provided as part of this solicitation Q&A. Requests for agency records on pricing may be submitted through the applicable FOIA process and will be reviewed for releasability.
- Period of performance of the incumbent contract
Response: 9/30/2020 to 9/29/2025.
- Any publicly available award documentation or reference links
Response: None that we are aware of.
5/4/2026: See attached amendment 1 which updates the SBCX link for the subcontracting plan.
See attached combined synopsis/solicitation.
Update #2 ·
5/4/2026: See attached amendment 1 which updates the SBCX link for the subcontracting plan.
See attached combined synopsis/solicitation.
Update #1 ·
See attached combined synopsis/solicitation.
Files
Notice history
| Notice | Type | Posted |
|---|---|---|
| Pharmaceutical Products for CDER Research Studies - IDIQ | Award Notice | |
| This notice | Solicitation | |
| Pharmaceutical Products for CDER Research Studies - IDIQ | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Contractor-Hosted Fully Integrated Records Facility (FIRF) IDIQ | FDA Office of Acquisition and Grant Services | Service-Disabled Veteran-Owned Small Business | |
| Epinephrine Injector | Medical Supply Chain | No set-aside | |
| 6505--Imatinib Tablets | National Acquisition Center | No set-aside | |
| Methylphenidate ER | Medical Supply Chain | No set-aside | |
| Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program | Defense Health Agency | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity